This review will discuss the androgen receptor signalling pathway, current treatments targeting androgen production and AR antagonists, moving forwards towards emerging treatment options for advanced castration resistant PCa (CRPC) and will consider how novel approaches to suppress androgen signalling may reduce or delay development of treatment-emergent NE-like PCa. This evidence concerns the gene AR and posterior cortical atrophy.